Drafting and Managing Pharmaceutical Safety Data Exchange Agreements

Some of the topics to be covered at this meeting include overview of the legal/policy landscape as it affects the terms of CTAs, clause by clause review, legal clauses, review of a Universitys CTA

Course overview

The effective management of the pharmacovigilance aspects of commercial agreements is essential for all parties involved. Ensuring the inclusion of key pharmacovigilance-relevant terms in agreements and monitoring compliance with them can be challenging, but is essential for compliance with current regulatory requirements relating to medicinal products.

This interactive seminar will address the key regulatory requirements relating to pharmacovigilance and discuss how to ensure that they are taken into account in various types of commercial arrangements. The emphasis will be on identifying the key terms needed in different types of agreement with a view to ensuring regulatory compliance and on a practical approach to drafting.

Who should attend

The seminar will be of interest to personnel involved in negotiating, preparing and managing commercial agreements of various types (for example, between co-marketers and with distributors, vendors and service providers) where the inclusion of pharmacovigilance terms and obligations is needed, including those working in legal, safety, commercial, and regulatory affairs departments.

Programme at a glance...

Types of commercial arrangement in the pharmaceutical industry

Contracts – the basics

Regulatory requirements and guidance on pharmacovigilance relevant to pharmaceutical commercial agreements

Key considerations in negotiating, drafting and managing agreements

Key pharmacovigilance terms for commercial agreements – overview

INTERACTIVE SESSION – Discussion and review of sample key clauses: co-marketing and distribution agreements

INTERACTIVE SESSION – Discussion and review of sample key clauses: co-promotion agreements, arrangements with vendors and service providers

Common problems, audit and inspection findings

Continuing professional development

This course qualifies for the following CPD programmes:

  • CPD certificate of attendance: 5.50 hours

Bespoke training

We can customise this course to meet the requirements of your organisation. Contact us to discuss your training requirements.

You may also be interested in

Previous customers include...

  • Accord
  • Actelion Pharmaceutical Ltd
  • AS Grindeks
  • Astellas Pharma Europe BV
  • Bayer
  • Bayer PLC
  • Besins Healthcare
  • Bilthoven Biologicals B.V.
  • Conforma NV
  • DADA Consultancy
  • Dompé Farmaceutici SpA
  • Eisai Europe Limited
  • Ferrer Interancional, S.A.
  • Ferring Pharmaceutical A/S
  • GE Healthcare
  • Glenmark Pharmaceuticals Europe R&F Ltd
  • Helsinn Healthcare S.A.
  • IRE-TEX INNOVATIONS LTD
  • Kyowa Kirin International plc.
  • Laboratoires Pierre Fabre
  • Mundipharma Research Ltd
  • Omega Pharma Innovation & Development
  • Panacea Pharma Projects
  • Pharmacovigilance Matters Limited
  • Porton Biopharma Limited
  • ProductLife
  • Takeda UK Ltd
  • Torbay Pharmaceuticals
  • Veterinary Medicines Directorate
  • Wortley Byers Law

1 day course well managed. Would need a 2nd day to go in depth in all types of SDEAS.

Viviane Bertuit, Auditor, Sanofi

Very interesting, insightful. I feel like I learnt a lot. Speakers kept us focused. Food was great!

Madeleine Redfern, European Legal Advisor, Glenmark Pharmaceuticals Europe Ltd

Broad based, clear definitions and examples, speakers extensive experience, preparation, management, auditing of SDEAS

Jennifer McDonough, Head of Safety Alliance Management, UCB Pharma Biosciences Inc.

All in all very well put together and covered a lot of details.

Yiannis Kaltabanopoulos, Pharmacovigilance Officer, Besins Healthcare

Well prepared. Good pace. Like review of worked examples and discussing some example languages.

Marisa Kirchner, , Roche Products Ltd

It was good that we could ask any questions and the course was interactive

Nataliya Korneeva, Manager, Les Laboratoires Servier

Good and clear from the speaker

Abdelkarim El-Abdellati, , SGS Belgium NV

Very good and achieved aims

Alan Jennings, Director of Regulatory Affairs, Porton Biopharma Limited

It was an interesting course with a lot of good and clear points. It was interactive which gives an added value as trainees mainly are there to get some practical issues solved. The presenter had very good knowledge of the topic.

Nathalie Dubois, Deputy QPPV, Omega Pharma Innovation & Development

Excellent

Andrea Domenico Pricca, , Dompé Farmaceutici SpA

Full of very important details and other interesting topics that linked - PSMF/Vendors

Charlotte Bunyan, Pharmacovigilance Manager, Takeda UK Ltd

Very well detailed and put together. Interactive and well paced. Many topics were covered and questions were answered by speakers in detail.

Jas Sangha, , Mundipharma Research Ltd

Thought it was appropriate for a group attending. Material was completely relevant.

Pooja Shah, Pharmacovigilance Manager, Cancer Research UK

Good clear communication

Nathalie Lilienthal, SDEA Manager, Sanofi-Aventis Recherche & Developpement

I was very pleased that one of the speakers was a lawyer. It was good to hear about the topic from a lawyer's perspective.

Anna Rozmyslowicz, PV System Manager, Aurobindo Pharma Ltd

Well presented and covered all aspects of drafting SDEA's

Sally Andrews, Head of Regulatory Affairs, Torbay Pharmaceuticals

Very well presented lectures that all the aspects of SDEA's that I wanted to know

Sally Andrews, Head of Regulatory Affairs, Torbay Pharmaceuticals